Leading the way to safer medication
 Crosscheck  Recommender

Belinostat

Description

Belinostat is a histone deacetylase (HDAC) inhibitor. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. It is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

ATC Classification

Code
Title
Category
L01XH04
Belinostat
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XH Histone deacetylase (HDAC) inhibitors

Trade names

Trade name
Countries

United States

Product Monographs

Monograph
Type
Country
BELEODAQ Powder for solution for injection
MPI, US: SPL/PLR
US